Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild and Dominik Cordier
Journal of Nuclear Medicine April 2024, 65 (4) 573-579; DOI: https://doi.org/10.2967/jnumed.123.266817
Christopher Eigler
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa McDougall
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Bauman
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bernhardt
2Department of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hentschel
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristine A. Blackham
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Nicolas
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melpomeni Fani
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Wild
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Cordier
3Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 65 no. 4 573-579
DOI 
https://doi.org/10.2967/jnumed.123.266817
PubMed 
38423782

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication October 5, 2023
  • Revision received January 5, 2024
  • Published online April 1, 2024.

Article Versions

  • previous version (February 29, 2024 - 10:11).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Christopher Eigler1,
  2. Lisa McDougall1,
  3. Andreas Bauman1,
  4. Peter Bernhardt2,
  5. Michael Hentschel1,
  6. Kristine A. Blackham1,
  7. Guillaume Nicolas1,
  8. Melpomeni Fani1,
  9. Damian Wild*,1 and
  10. Dominik Cordier*,3
  1. 1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  2. 2Department of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden; and
  3. 3Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
  1. For correspondence or reprints, contact Damian Wild (damian.wild{at}usb.ch).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 8 Citations
  • 7 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
    Sarah D. Busslinger, Ana Katrina Mapanao, Kristel Kegler, Peter Bernhardt, Fabienne Flühmann, Julia Fricke, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 13
  • Radioligand therapies in meningioma: Evidence and future directions
    Maximilian J Mair, Emeline Tabouret, Derek R Johnson, Erik P Sulman, Patrick Y Wen, Matthias Preusser, Nathalie L Albert
    Neuro-Oncology 2024 26 Supplement_9
  • Do we need dosimetry for the optimization of theranostics in CNS tumors?
    Francesco Cicone, Silvano Gnesin, Giulia Santo, Caroline Stokke, Mirco Bartolomei, Giuseppe Lucio Cascini, Giuseppe Minniti, Giovanni Paganelli, Antoine Verger, Marta Cremonesi
    Neuro-Oncology 2024 26 Supplement_9
  • Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
    Giulia Santo, Gianpaolo di Santo, Francesco Cicone, Irene Virgolini
    Journal of Neuroendocrinology 2025 37 3
  • 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review
    Caroline BOURSIER, Timothée ZARAGORI, Laëtitia IMBERT, Antoine VERGER
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2024 68 3
  • Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models
    Anna Terasawa, Kazuhiro Shimazu, Hiroshi Nanjo, Masatomo Miura, Hiroyuki Shibata
    World Journal of Experimental Medicine 2025 15 2
  • Radiotheranostic landscape: A review of clinical and preclinical development
    Ha H. Tran, Aiko Yamaguchi, H. Charles Manning
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 7

Article usage

Article usage: March 2024 to May 2025

AbstractFullPdf
Feb 2024531910
Mar 2024411286125
Apr 2024590539143
May 20243093322
Jun 20243221111
Jul 20245781311
Aug 20244342917
Sep 20242644422
Oct 20245021048
Nov 20243424866
Dec 20244318956
Jan 2025198540
Feb 20251912049
Mar 20252511657
Apr 20251610172
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (4)
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Journal of Nuclear Medicine Apr 2024, 65 (4) 573-579; DOI: 10.2967/jnumed.123.266817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Journal of Nuclear Medicine Apr 2024, 65 (4) 573-579; DOI: 10.2967/jnumed.123.266817
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
  • Google Scholar

More in this TOC Section

  • [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease
  • Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View
  • Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • meningioma
  • peptide receptor radionuclide therapy
  • DOTA-JR11
  • DOTATOC
SNMMI

© 2025 SNMMI

Powered by HighWire